THE EFFECTS OF THE NEW ANTIPSYCHOTIC MEDICATIONS ON MOTHERS AND BABIES

Main Article Content

Irena Nulman

Keywords

Pregnancy, pregnancy outcome, malformations, second generation antipsychotics, atypical antipsychotics

Abstract

Second generation antipsychotics are widely used by thousands of pregnant women worldwide in order to control their psychiatric disorders. The clinical profiles of these drugs have improved, specifically the decreased risk of hyperprolactinemia, which has increased fertility in female patients. However, the reproductive safety of second-generation antipsychotics remains undefined and controversial. The aim of this presentation is to synthesize the available evidence-based information into a systematic review of the safety in pregnancy of this group of drugs (in mono -and polytherapy ).

Abstract 297 | PDF Downloads 229

References

1. World Health Organization. Mental health: Gender and women's mental health [Internet]. Copenhagen (DK): World Health Organization; c2014 [cited 2014 Jul 28]. Available from: http://www.who.int/mental_health/prevention/ge nderwomen/en
2. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM -IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 [cited 2014 Jul 28];62(6):593- 602. Available from: http://archpsyc.jamanetwork.com/article.aspx?ar ticleid=208678
3. Andersson L, Sundström -Poromaa I, Bixo M, et al. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 2003;189(1):148- 154.
4. Vesga -López O, Blanco C, Keyes K, et al. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry 2008 [cited 2014 Jul 28];65(7):805- 815. Available from: http://archpsyc.jamanetwork.com/article.aspx?ar ticleid=482762
5. Nicholson J, Biebel K, Williams V, et al. Prevalence of parenthood in adults with mental illness: implications for state and federal policymakers, programs, and providers. In: Manderscheid RW, Henderson MJ, editors. Center for Mental Health Services. Mental Health, United States, 2002. DHHS Pub No. (SMA) 3938. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2004 [cited 2014 Sep 19]. Chapter 10, p. 120- 137. Available from: http://escholarship.umassmed.edu/cgi/viewconte nt.cgi?article=1148&context=psych_pp
6. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27- 38.
7. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000 [cited 2014 Jul 28];321(7273):1371- 1376. Available from: http://www.bmj.com/cgi/pmidlookup?view=lon g&pmid=11099280
8. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off -label use of antipsychotic medications in the United States, 1995 -2008. Pharmacoepidemiol Drug Saf 2011 [cited 2014 Jul 28];20(2):177- 184. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21254289
9. Centorrino F, Cincotta SL, Talamo A, et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry 2008;49(1):65- 69.
10. Frye MA, Ketter TA, Leverich GS, et al. Increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61(1):9- 15.
11. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004 [cited 2014 Sep 19];161(4):700- 706. Available from: http://ajp.psychiatryonline.org/article.aspx?articl eid=176738
12. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010 [cited 2014 Jul 28];36(3):518- 544. Available from: http://www.ncbi.nlm.nih.gov/pmc/ articles/pmid/ 18787227
13. Gentile S. Pregnancy exposure to serotonin reuptake inhibitors and the risk of spontaneous abortions. CNS Spectr 2008;13(11):960- 966.
14. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28(3):279- 288.
15. Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol 2013;33(4):453- 462.
16. Sadowski A, Todorow M, Yazdani Brojeni P, et al. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open 2013 [cited 2014 Jul 28];3(7). pii: e003062. Available from: http://bmjopen.bmj.com/cgi/pmidlookup?view=l ong&pmid=23852139

Most read articles by the same author(s)